J Rheum Dis.  2021 Jan;28(1):1-3. 10.4078/jrd.2021.28.1.1.

What Can Lipids in Anti-neutrophil Cytoplasmic Antibody-associated Vasculitis Tell Us?

• Choi CB

• KMID: 2510336
• DOI: http://doi.org/10.4078/jrd.2021.28.1.1

Reference

1. Klinger H. 1931; [Grenzformen der periarteritis nodosa]. Frankf Z Pathol. 42:455–80. German.

2. van der Woude FJ, Rasmussen N, Lobatto S, Wiik A, Permin H, van Es LA, et al. 1985; Autoantibodies against neutrophils and monocytes: tool for diagnosis and marker of disease activity in Wegener's granulomatosis. Lancet. 1:425–9. DOI: 10.1016/S0140-6736(85)91147-X.

3. Bossuyt X, Cohen Tervaert JW, Arimura Y, Blockmans D, Flores-Suárez LF, Guillevin L, et al. 2017; Position paper: revised 2017 international consensus on testing of ANCAs in granulomatosis with polyangiitis and microscopic polyangiitis. Nat Rev Rheumatol. 13:683–92. DOI: 10.1038/nrrheum.2017.140. PMID: 28905856. PMID: 2857806.

4. Osman MS, Tervaert JWC. 2019; Anti-neutrophil cytoplasmic antibodies (ANCA) as disease activity biomarkers in a "personalized medicine approach" in ANCA-associated vasculitis. Curr Rheumatol Rep. 21:76. DOI: 10.1007/s11926-019-0872-3. PMID: 31879818.

5. Merkel PA, Aydin SZ, Boers M, Direskeneli H, Herlyn K, Seo P, et al. 2011; The OMERACT core set of outcome measures for use in clinical trials of ANCA-associated vasculitis. J Rheumatol. 38:1480–6. DOI: 10.3899/jrheum.110276. PMID: 21724720. PMCID: PMC3645858.

6. Monti S, Quinn KA, Christensen R, Jayne D, Langford C, Lanier GE, et al. 2020; Use and reporting of outcome measures in randomized trials for anti-neutrophil cytoplasmic antibody-associated vasculitis: a systematic literature review. Semin Arthritis Rheum. 50:1314–25. DOI: 10.1016/j.semarthrit.2020.09.010. PMID: 33130459.

7. Csernok E, Hellmich B. 2020; Usefulness of vasculitis biomarkers in the era of the personalized medicine. Autoimmun Rev. 19:102514. DOI: 10.1016/j.autrev.2020.102514. PMID: 32171919.

8. Ahn SS, Jung SM, Song JJ, Park YB, Lee SW. 2018; Neutrophil to lymphocyte ratio at diagnosis can estimate vasculitis activity and poor prognosis in patients with ANCA-associated vasculitis: a retrospective study. BMC Nephrol. 19:187. DOI: 10.1186/s12882-018-0992-4. PMID: 30064369. PMCID: PMC6069981.

9. Park HJ, Jung SM, Song JJ, Park YB, Lee SW. 2018; Platelet to lymphocyte ratio is associated with the current activity of ANCA-associated vasculitis at diagnosis: a retrospective monocentric study. Rheumatol Int. 38:1865–71. DOI: 10.1007/s00296-018-4125-y. PMID: 30088046.

10. Přikryl P, Hrušková Z, Konopásek P, Hladinová Z, Tesař V, Vokurka M. 2018; Serum hepcidin is increased in ANCA-associated vasculitis and correlates with activity markers. Physiol Res. 67:945–54. DOI: 10.33549/physiolres.933765. PMID: 30204470.

11. Berti A, Warner R, Johnson K, Cornec D, Schroeder DR, Kabat BF, et al. RAVE-ITN Research Group. 2019; The association of serum interleukin-6 levels with clinical outcomes in antineutrophil cytoplasmic antibody-associated vasculitis. J Autoimmun. 105:102302. DOI: 10.1016/j.jaut.2019.07.001. PMID: 31320177. PMCID: PMC7217333.

12. Borowiec A, Dąbrowski R, Kowalik I, Rusinowicz T, Hadzik-Błaszczyk M, Krupa R, et al. 2020; Elevated levels of d-dimer are associated with inflammation and disease activity rather than risk of venous thromboembolism in patients with granulomatosis with polyangiitis in long term observation. Adv Med Sci. 65:97–101. DOI: 10.1016/j.advms.2019.12.007. PMID: 31923773.

13. Yoon T, Ahn SS, Pyo JY, Song JJ, Park YB, Lee SW. 2020; Dec. 18. Serum vitamin D level correlates with disease activity and health-related quality of life in antineutrophil cytoplasmic antibody-associated vasculitis. Z Rheumatol. [Epub]. DOI: 10.1007/s00393-020-00949-2. DOI: 10.1007/s00393-020-00949-2. PMID: 33340057.

14. Yoon T, Ahn SS, Song JJ, Park YB, Lee SW. 2020; Soluble lectin-like oxidized low-density lipoprotein receptor 1 is inversely correlated with the activity of ANCA-associated vasculitis. Yonsei Med J. 61:720–5. DOI: 10.3349/ymj.2020.61.8.720. PMID: 32734736. PMCID: PMC7393288.

15. Yoon T, Ahn SS, Yoo J, Yoo BW, Kwon HC, Jung SM, et al. 2020; Serum Mannose-binding lectin levels are correlated with the disease activity of antineutrophil cytoplasmic antibody-associated vasculitis: a single-center study. Tohoku J Exp Med. 251:117–23. DOI: 10.1620/tjem.251.117. PMID: 32581191.

16. Wallace ZS, Fu X, Liao K, Kallenberg CGM, Langford CA, Merkel PA, et al. 2019; Disease activity, antineutrophil cytoplasmic antibody type, and lipid levels in antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheumatol. 71:1879–87. DOI: 10.1002/art.41006. PMID: 31162829. PMCID: PMC6944270.

17. Houben E, Penne EL, Voskuyl AE, van der Heijden JW, Otten RHJ, Boers M, et al. 2018; Cardiovascular events in anti-neutrophil cytoplasmic antibody-associated vasculitis: a meta-analysis of observational studies. Rheumatology (Oxford). 57:555–62. DOI: 10.1093/rheumatology/kex338. PMID: 29029294.

18. Ahn SS, Yoon T, Song JJ, Park YB, Lee SW. 2020; Lipid profiles in anti-neutrophil cytoplasmic antibody-associated vasculitis: a cross-sectional analysis. J Rheum Dis. 27:261–9. DOI: 10.4078/jrd.2020.27.4.261.

19. Soria-Florido MT, Castañer O, Lassale C, Estruch R, Salas-Salvadó J, Martínez-González MÁ, et al. 2020; Dysfunctional high-density lipoproteins are associated with a greater incidence of acute coronary syndrome in a population at high cardiovascular risk: a nested case-control study. Circulation. 141:444–53. DOI: 10.1161/CIRCULATIONAHA.119.041658. PMID: 31941372.

20. Walldius G, Jungner I, Holme I, Aastveit AH, Kolar W, Steiner E. 2001; High apolipoprotein B, low apolipoprotein A-I, and improvement in the prediction of fatal myocardial infarction (AMORIS study): a prospective study. Lancet. 358:2026–33. DOI: 10.1016/S0140-6736(01)07098-2. PMID: 11755609.

21. Robertson J, Peters MJ, McInnes IB, Sattar N. 2013; Changes in lipid levels with inflammation and therapy in RA: a maturing paradigm. Nat Rev Rheumatol. 9:513–23. DOI: 10.1038/nrrheum.2013.91. PMID: 23774906.

22. Ridker PM, Danielson E, Fonseca FA, Genest J, Gotto AM Jr, Kastelein JJ, et al. JUPITER Trial Study Group. 2009; Reduction in C-reactive protein and LDL cholesterol and cardiovascular event rates after initiation of rosuvastatin: a prospective study of the JUPITER trial. Lancet. 373:1175–82. DOI: 10.1016/S0140-6736(09)60447-5. PMID: 19329177.

23. Kim SY, Yu M, Morin EE, Kang J, Kaplan MJ, Schwendeman A. 2020; High-density lipoprotein in lupus: disease biomarkers and potential therapeutic strategy. Arthritis Rheumatol. 72:20–30. DOI: 10.1002/art.41059. PMID: 31350818. PMCID: PMC6935404.